Application of lectin combination in preparation of chip for coronary heart disease diagnosis, pantovascular disease diagnosis and distinguishing of coronary heart disease and pantovascular disease

Abstract

The invention relates to application of a lectin chip, in particular to application of a lectin combination in preparation of chips for coronary heart disease diagnosis, ubiquitous vascular disease diagnosis and distinguishing of coronary heart disease and ubiquitous vascular disease, and aims to overcome the defect that in the prior art, an effective specific diagnosis marker and an efficient screening method for PVD (Physical Vapor Deposition) and clinical manifestation types thereof are lacked. When the lectin combination is applied to preparation of the coronary heart disease diagnosis chip, the lectin combination comprises at most 24 types of lectin such as PSA, UEA-I and WGA; when the lectin combination is applied to preparation of the tablet for diagnosing the general vascular disease, the lectin combination comprises at most 25 types of lectin such as PSA, UEA-I, WGA and the like; when the lectin combination is applied to preparation of the chip for distinguishing the coronary heart disease from the ubiquitous vascular disease, the lectin combination comprises at most 30 types of lectin such as PSA, UEA-I, WGA and the like.

Description

Technical Field

[0001] The present invention relates to the application of lectin chips, and in particular to the application of lectin combinations in preparing chips for diagnosing coronary heart disease, diagnosing panvascular diseases, and distinguishing between coronary heart disease and panvascular diseases. Background Art

[0002] According to the World Health Organization, cardiovascular and cerebrovascular diseases rank first among the diseases that cause human death. Faced with the life threat brought by such diseases, in recent years, scholars at home and abroad have proposed the concept of "pan-vascular disease" management, which has gradually entered the public's field of vision. Pan-vascular refers to the human vascular system, which is a complex network composed of arteries, veins, lymphatic vessels, etc. It is the "irrigation channel" of important organs of the body and the "lifeline" of human health. Pan-vascular diseases (PVD) are a group of systemic vascular diseases with vascular lesions (95% of which are atherosclerosis) as common pathological characteristics, which mainly endanger important organs such as the heart, brain, kidneys, limbs and aortas. Pan-vascular diseases are systemic vascular diseases based on atherosclerosis, which mainly include coronary heart disease (CHD), ischemic stroke (CI), renal artery stenosis (RAD), peripheral artery disease (PAD), and abdominal aortic aneurysm (AAA). The anatomical shape of the heart's arteries looks like an inverted crown, so the heart's arteries are called coronary arteries, which are arteries that look like crowns. When atherosclerosis occurs in the heart arteries, it is called coronary atherosclerosis. If the stenosis caused by coronary atherosclerosis exceeds 50%, it is a heart disease, called coronary atherosclerotic heart disease, or CHD for short. It may be asymptomatic in the early stage or may manifest as angina pectoris after exercise; in the early stage of ischemic stroke (CI), the patient is generally conscious, in the middle stage there will be disturbance of consciousness, medullary paralysis, etc., in the late stage there will be complications of brain herniation, which is often life-threatening or leads to brain death; in the early stage of abdominal aortic aneurysm (AAA), there are no specific symptoms, and the patient may occasionally feel the pulsation of the abdominal artery or can touch the arterial pulsation with the hand. If the aneurysm ruptures, due to the large blood flow in the aorta, the patient may experience severe abdominal pain, rapid hypotension, and death from hemorrhagic shock.

[0003] PVD mainly harms important organs such as the heart, brain, kidneys, limbs and aorta. Its timely detection is particularly important because PVD has begun to develop before obvious symptoms appear, such as abnormal endothelial function, thickening of vascular walls, plaques and thrombosis. Due to the lack of effective diagnostic markers specific to PVD and its clinical manifestations and efficient screening methods for PVD and its clinical manifestations, timely diagnosis of PVD before onset remains challenging. In addition, due to the subdivision of disciplines, pan-vascular diseases represented by coronary artery disease, stroke, and peripheral arterial disease are included in different disciplines and are managed separately by different departments such as cardiovascular medicine, neurology, cardiac surgery, neurosurgery, vascular surgery, and radiology. Each discipline pays too much attention to local lesions and ignores the problem of systemic vascular lesions, resulting in significant differences in the diagnosis and treatment strategies of different disciplines for the same disease, making it difficult to effectively identify PVD and take appropriate treatment measures for it as early as possible. Summary of the invention

[0004] The purpose of the present invention is to address the shortcomings of the prior art in the lack of effective specific diagnostic markers and efficient screening methods for PVD and its clinical manifestations, and to provide the use of lectin combinations in the preparation of chips for the diagnosis of coronary heart disease, pan-vascular disease, and for distinguishing between coronary heart disease and pan-vascular disease, so as to provide earlier common and personalized treatment and intervention for PVD and its clinical manifestations, thereby reducing the incidence of related complications and the risk of death.

[0005] The concept of the present invention:

[0006] Studies in recent years have shown that the occurrence and development of PVD may lead to abnormal glycosylation of proteins, and abnormal glycosylation may aggravate the course of PVD. Therefore, detecting abnormal expression of protein glycosylation in the blood may help to timely discover PVD and its clinical manifestations, and provide earlier common and personalized treatment and intervention for PVD and its clinical manifestations, thereby reducing the incidence and risk of death of related complications. Therefore, the present invention studies the sugar chain structure of serum glycoproteins in three groups of samples from healthy volunteers, patients with coronary heart disease and pan-vascular disease, and obtains the relationship between the changes in the sugar chain structure of serum glycoproteins in each group and the occurrence and development of the disease. According to this principle, specific lectins are used to prepare diagnostic and differentiation chips for coronary heart disease and pan-vascular disease, which helps to detect CHD and PVD early.

[0007] In order to achieve the above objectives and complete the above inventive concept, the technical solutions provided by the present invention are as follows:

[0008] A use of a lectin combination in preparing a coronary heart disease diagnostic chip is special in that the lectin combination is:

[0009] A combination of lectins PSA, UEA-I, and WGA, or a combination of lectins PSA, UEA-I, and WGA with one or more of lectins PTL-I, PTL-II, ACA, BPL, BS-L, EEL, HHL, MALL-II, PHA-E+L, STL, SJA, LEL, PWM, MAL-I, and GSL-I, and a combination of lectins DSA, ECA, LCA, and WFA, or a combination of lectins DSA, ECA, LCA, and WFA with one or more of lectins Jaclin, RCA120, AAL, and LTL.

[0010] Further, the lectin combination is:

[0011] The combination of lectins PSA, UEA-I, WGA and lectins PTL-I, PTL-II, ACA, BPL, BS-L, EEL, HHL, MALL-II, PHA-E+L, STL, SJA, LEL, PWM, MAL-I, GSL-I, and the combination of lectins DSA, ECA, LCA, WFA and lectins Jaclin, RCA120, AAL, LTL.

[0012] At the same time, the present invention also provides an application of a lectin combination in the preparation of a pan-vascular disease diagnostic chip, the special feature of which is that the lectin combination is:

[0013] A combination of lectins PSA, UEA-I, and WGA, or a combination of lectins PSA, UEA-I, and WGA with one or more of lectins PTL-I, PTL-II, RCA120, AAL, and LTL, and a combination of lectins DSA, ECA, WFA, and LCA, or a combination of lectins DSA, ECA, WFA, and LCA with one or more of lectins ACA, ConA, DBA, EEL, GSL-I, GSL-II, PNA, SJA, PWM, NPA, MPL, HHL, and MAL-II.

[0014] Further, the lectin combination is:

[0015] The combinations of lectins PSA, UEA-I, WGA with lectins PTL-I, PTL-II, RCA120, AAL, LTL, and the combinations of lectins DSA, ECA, WFA, LCA with lectins ACA, ConA, DBA, EEL, GSL-I, GSL-II, PNA, SJA, PWM, NPA, MPL, HHL, MAL-II.

[0016] At the same time, the present invention also provides an application of a lectin combination in preparing a chip for distinguishing coronary heart disease and panvascular disease, the special feature of which is that the lectin combination is:

[0017] A combination of lectins PSA, UEA-I, and WGA, or a combination of lectins PSA, UEA-I, and WGA with one or more of lectins RCA120, AAL, LTL, Jaclin, and LCA, and a combination of lectins ECA and WFA, or a combination of lectins ECA and WFA with one or more of lectins ACA, BPL, BS-I, VVA, DBA, EEL, GSL-I, GSL-II, HHL, STL, MAL-I, MAL-II, MPL, NPA, PHA-E+L, PNA, PWM, SJA, ConA, and LEL.

[0018] Further, the lectin combination is:

[0019] The combination of lectins PSA, UEA-I, WGA with lectins RCA120, AAL, LTL, Jaclin, LCA, and the combination of lectins ECA, WFA with lectins ACA, BPL, BS-I, VVA, DBA, EEL, GSL-I, GSL-II, HHL, STL, MAL-I, MAL-II, MPL, NPA, PHA-E+L, PNA, PWM, SJA, ConA, LEL.

[0020] Beneficial effects of the present invention:

[0021] The present invention utilizes the application of lectin combinations in the preparation of chips for diagnosing and differentiating coronary heart disease and panvascular disease. The chip prepared using a specific lectin combination can identify all corresponding sugar chain structures in a sample in one test, and can produce results immediately after the test is taken, thereby improving detection efficiency and accuracy. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 It is the type of upregulated expression of serum glycoprotein sugar chain structure in the CHD group compared with the HV group in the embodiment of the present invention;

[0023] Figure 2 It is the type of down-regulated expression of serum glycoprotein sugar chain structure in the CHD group compared with the HV group in the embodiment of the present invention;

[0024] Figure 3 It is the type of upregulated expression of serum glycoprotein sugar chain structure in the PVD group compared with the HV group in the embodiment of the present invention;

[0025] Figure 4It is the type of down-regulated expression of serum glycoprotein sugar chain structure in the PVD group compared with the HV group in the embodiment of the present invention;

[0026] Figure 5 It is the type of upregulated expression of serum glycoprotein sugar chain structure in the CHD group compared with the PVD group in the embodiment of the present invention;

[0027] Figure 6 It is the type of down-regulated expression of serum glycoprotein sugar chain structure in the CHD group compared with the PVD group in the embodiment of the present invention;

[0028] Figure 7 : are confusion matrix diagrams of the five models in the embodiment of the present invention; wherein A is a confusion matrix diagram of the KNN model, B is a confusion matrix diagram of the LR model, C is a confusion matrix diagram of the LR model, D is a confusion matrix diagram of the MLP model, and E is a confusion matrix diagram of the SVM model;

[0029] Figure 8 1 is the ROC curve diagram of the five models in the embodiment of the present invention; wherein A is the ROC curve diagram of the KNN model, B is the ROC curve diagram of the LR model, C is the ROC curve diagram of the LR model, D is the ROC curve diagram of the MLP model, and E is the ROC curve diagram of the SVM model. DETAILED DESCRIPTION

[0030] This study used high-throughput lectin chip technology to compare the sugar chain structures of serum glycoproteins in three groups of samples: healthy volunteers (HV), patients with coronary heart disease (CHD), and patients with panvascular disease (PVD), to explore the relationship between changes in the sugar chain structures of serum glycoproteins in each group and the occurrence and development of the disease. At the same time, combined with the data obtained from the lectin chip experiment and the machine learning algorithm, a diagnostic model for CHD and PVD was established and evaluated.

[0031] 1. Experimental Methods

[0032] (1) Serum samples from 394 patients (88 HV patients, 217 CHD patients, and 89 PVD patients) were analyzed for glycoprotein sugar chain structure using lectin microarray technology;

[0033] (2) The lectin fluorescence values ​​of all samples were then normalized and visualized for analysis;

[0034] (3) Establish and evaluate the diagnostic model. The fluorescence normalized data of all samples were divided into a training set and a test set in a ratio of 7:3. Five machine learning algorithm models were constructed based on the training set data, namely K nearest neighbor (KNN), logistic regression (MLP), multilayer perceptron (LR), random forest (RF), and support vector machine (SVM). The test set was then used to evaluate the performance of the established diagnostic model.

[0035] 2. Experimental Results

[0036] There were different degrees of differences in sugar chain structure expression among the three groups of HV, CHD and PVD patients.

[0037] The specific performance is as follows:

[0038] (1) Differences in sugar chain structures of serum glycoproteins between the HV group and the CHD group

[0039] Depend on Figure 1 It can be seen that compared with the HV group, the CHD group had up-regulated expression of 18 sugar chain structures of serum glycoproteins recognized and bound by lectins: the sugar chain structures recognized and bound by 12 lectins with extremely significant up-regulated expression (****p<0.0001) were Galβ1-3GalNAcα-Ser / Thr sugar chain structure recognized by ACA, Galβ1-3GalNAc sugar chain structure recognized by BPL, α-Gal / GalNAc sugar chain structure recognized by BS-L, Galα1-3(Fucα1-2)Gal sugar chain structure recognized by EEL, Non-substitutedα-1,6Man sugar chain structure recognized by HHL, Siaα2-3Galβ1-4Glc(NAc) sugar chain structure recognized by MALL-II, Bisecting GlcNAc and Biantennary N-glycan sugar chain structure, Fucα-N-acetylchitobioseMan sugar chain structure recognized by PSA, αGalNAc andαGal sugar chain structure recognized by PTL-I, Gal sugar chain structure recognized by PTL-II, (GlcNAc) recognized by STL n Sugar chain structure and Fucα1-2Galβ1-4Glc(NAc) sugar chain structure recognized by UEA-I; the sugar chain structure recognized and bound by a lectin with very significant up-regulated expression (***p<0.001) is the Terminal GalNAc and Gal sugar chain structure recognized by SJA; the sugar chain structure recognized and bound by a lectin with very significant up-regulated expression (**p<0.01) is Multivalent Sia and(GlcNAc) recognized by WGA n Sugar chain structure; Sugar chain structures recognized and bound by the four lectins with significantly upregulated expression (*p<0.05): Poly-LacNAc and (GlcNAc) recognized by LEL nSugar chain structure, GlcNAc sugar chain structure recognized by PWM, Galβ1-4GlcNAc sugar chain structure recognized by MAL-I and α-GalNAc / Gal and GalNAcαSer / Thr(Tn) sugar chain structure recognized by GSL-I.

[0040] Depend on Figure 2 It can be seen that compared with the HV group, the CHD group had down-regulated expression of serum glycoprotein sugar chain structures recognized by 8 lectins: the sugar chain structures recognized by 6 lectins with extremely significant down-regulated expression (****p<0.0001) were GlcNAc sugar chain structures recognized by DSA, Galβ1-4GlcNAc sugar chain structures recognized by ECA, Fucα1-6GlcNAc(core) sugar chain structures recognized by LCA, Galβ1-3GalNAcα-Ser / Thr(T), GalNAcα-Ser / Thr(T) sugar chain structures recognized by Jaclin, Gal,GlcNAc sugar chain structures recognized by RCA120 and GalNAcα / β1-3 / 6Gal sugar chain structures recognized by WFA; the sugar chain structures recognized by 2 lectins with very significant down-regulated expression (***p<0.001) were Terminal 1 / 2 / 3GalNAc recognized by AAL. The sugar chain structures of Fucα1-6GlcNAc, Fucα1-3(Galβ1-4)GlcNAc and the sugar chain structures of SLex, Lex and Fucα1-3GlcNAc(core) recognized by LTL.

[0041] (2) Differences in sugar chain structures of serum glycoproteins between the HV and PVD groups

[0042] Depend on Figure 3 It can be seen that compared with the HV group, the PVD group had up-regulated expression of serum glycoprotein sugar chain structures recognized and bound by 8 lectins: the extremely significantly up-regulated sugar chain structures recognized and bound by 8 lectins (****p<0.0001) were Terminal Fucα1-6GlcNAc and Fucα1-3(Galβ1-4)GlcNAc sugar chain structures recognized by AAL, SLex, Lex and Fucα1-3GlcNAc(core) sugar chain structures recognized by LTL, Fucα-N-acetylchitobioseMan sugar chain structure recognized by PSA, sugar chain structure recognized by PTL-I, α-GalNAc / Gal sugar chain structure recognized by PTL-II, Gal and GlcNAc sugar chain structures recognized by RCA120, Fucα1-2Galβ1-4GlcNAc sugar chain structure recognized by UEA-I and Multivalent Sia, (GlcNAc) nSugar chain structure.

[0043] Depend on Figure 4 It can be seen that compared with the HV group, the PVD group had 17 serum glycoprotein sugar chain structures recognized and bound by lectins down-regulated: the 13 sugar chain structures recognized and bound by lectins with extremely significant down-regulation (****p<0.0001) were Galβ1-3GalNAcα-Ser / Thr sugar chain structure recognized by ACA, Branched and terminalMan, Terminal GlcNAc sugar chain structure, GalNAcα-Ser / Thr(Tn) and GalNAcα1-3Gal sugar chain structures recognized by DBA, GlcNAc sugar chain structure recognized by DSA, Galβ1-4GlcNAc sugar chain structure recognized by ECA, Galα1-3(Fucα1-2)Gal sugar chain structure recognized by EEL, α-GalNAc, α-Gal, and GalNAcαSer / Thr(Tn) sugar chain structures recognized by GSL-I, GlcNAc and Galactosylated N-glycan sugar chain structures recognized by GSL-II, Galβ1-3GalNAcα-Ser / Thr(T) sugar chain structure recognized by PNA, GalNAcα / β1-3 / 6Gal sugar chain structure recognized by WFA, and Terminal recognized by SJA GalNAc / Gal sugar chain structure, GlcNAc sugar chain structure recognized by PWM and Non-substitutedα1-6Man sugar chain structure recognized by NPA; the sugar chain structures recognized and bound by the two lectins with very significant down-regulated expression (***p<0.001) were the α-GalNAc sugar chain structure recognized by MPL and the Fucα1-6GlcNAc (core) sugar chain structure recognized by LCA; the sugar chain structures recognized and bound by the two lectins with very significant down-regulated expression (**p<0.01) were the Non-substitutedα-1,6Man sugar chain structure recognized by HHL and the Siaα2-3Galβ1-4GlcNAc sugar chain structure recognized by MAL-II.

[0044] (3) Differences in sugar chain structures of serum glycoproteins between the PVD and CHD groups

[0045] Depend on Figure 5It can be seen that compared with the CHD group, the PVD group had up-regulated expression of serum glycoprotein sugar chain structures recognized by 8 lectins: the sugar chain structures recognized by the 8 lectins that were extremely up-regulated (****p<0.0001) were Terminal Fucα1-6GlcNAc and Fucα1-3(Galβ1-4)GlcNAc sugar chain structures recognized by AAL, Galβ1-3GalNAcα-Ser / Thr(T), GalNAcα-Ser / Thr(T) sugar chain structures recognized by Jaclin, Fucα1-6GlcNAc(core) sugar chain structure recognized by LCA, SLex, Lex and Fucα1-3GlcNAc (core) sugar chain structure, Fucα-N-acetylchitobioseMan sugar chain structure recognized by PSA, Gal, GlcNAc sugar chain structure recognized by RCA120, Fucα1-2Galβ1-4GlcNAc sugar chain structure recognized by UEA-I and Multivalent Sia, (GlcNAc) recognized by WGA n Sugar chain structure.

[0046] Depend on Figure 6 It can be seen that compared with the CHD group, the PVD group had down-regulated expression of 22 lectins that recognized and bound serum glycoprotein sugar chain structures: the 19 lectins that were extremely significantly down-regulated (****p<0.0001) were the Galβ1-3GalNAcα-Ser / Thr sugar chain structure recognized by ACA, the Galβ1-3GalNAc sugar chain structure recognized by BPL, the α-Gal / GalNAc sugar chain structure recognized by BS-I, the GalNAc, GalNAcα-Se and GalNAcα-Ser / Thr sugar chain structures recognized by VVA, and the α-Gal / GalNAc sugar chain structures recognized by BS-I. r / Thr(Tn) sugar chain structure, GalNAcα-Ser / Thr(Tn) and GalNAcα1-3Gal sugar chain structures recognized by DBA, Galβ1-4GlcNAc sugar chain structure recognized by ECA, Galα1-3(Fucα1-2)Gal sugar chain structure recognized by EEL, α-GalNAc / αGal and GalNAcαSer / Thr(Tn) sugar chain structures recognized by GSL-I, GlcNAc and Galactosylated N-glycan sugar chain structures recognized by GSL-II, Non-substitutedα-1,6Man sugar chain structure recognized by HHL, (GlcNAc) recognized by STL nSugar chain structure: Galβ1-4GlcNAc sugar chain structure recognized by MAL-I, Siaα2-3Galβ1-4GlcNAc sugar chain structure recognized by MAL-II, α-GalNAc sugar chain structure recognized by MPL, Non-substitutedα1-6Man sugar chain structure recognized by NPA, Bisecting GlcNAc, biantennary N-glycan, tetra-antennary N-glycan sugar chain structure recognized by PHA-E+L, Galβ1-3GalNAcα-Ser / Thr(T) sugar chain structure recognized by PNA, GlcNAc sugar chain structure recognized by PWM and Terminal GalNAc / Gal sugar chain structure recognized by SJA; The sugar chain structures recognized and bound by the two lectins with very significantly down-regulated expression (***p<0.001) were Branched and terminal Man and Terminal GlcNAc sugar chain structure and GalNAcα / β1-3 / 6Gal sugar chain structure recognized by WFA; the sugar chain structure recognized and bound by a lectin with significantly downregulated expression (*p<0.05) is Poly-LacNAc and (GlcNAc) recognized by LEL n Sugar chain structure.

[0047] (4) Five machine learning algorithm models were constructed based on the training set data and verified using the test set. The following results were obtained: In the test, the SVM model performed best. Figure 7 and Figure 8 As shown in Table 1, the SVM model has the highest overall accuracy and area under the receiver operating characteristic curve (AUC), which are 0.90 and 0.92, respectively. In the HV group, the KNN, RF, and SVM models performed perfectly, as shown in Table 1, with sensitivity and specificity of 1.0. For the CHD group, the SVM and RF models had the highest sensitivity, reaching 0.95, and specificity of 0.84 and 0.80, respectively. This shows that the two models can well identify patients with coronary heart disease in the CHD group, but there are also some misjudgments, among which the specificity of the SVM model is slightly higher than that of the RF. In the PVD group, the SVM model has a sensitivity of 0.70 and a specificity of 0.97, which is the best performance among all models. Although the SVM model does not have the highest sensitivity in the PVD group, its specificity is very high, indicating that the model is more accurate in identifying PVD patients and has fewer misjudgments. Overall, the SVM model performed most stably and well in each group, especially in the CHD and PVD groups, showing high sensitivity and specificity, and was the best performing model in this test.

[0048] Table 1 Results of model sensitivity and specificity tests

[0049]

[0050]

Claims

1. Application of a lectin combination in the preparation of a coronary heart disease diagnostic chip, characterized in that: The lectin combination is: A combination of lectins PSA, UEA-I, and WGA, or a combination of lectins PSA, UEA-I, and WGA with one or more of lectins PTL-I, PTL-II, ACA, BPL, BS-L, EEL, HHL, MALL-II, PHA-E+L, STL, SJA, LEL, PWM, MAL-I, and GSL-I, and a combination of lectins DSA, ECA, LCA, and WFA, or a combination of lectins DSA, ECA, LCA, and WFA with one or more of lectins Jaclin, RCA120, AAL, and LTL.

2. The use of the lectin combination according to claim 1 in preparing a coronary heart disease diagnostic chip, characterized in that: The lectin combination is: The combination of lectins PSA, UEA-I, WGA and lectins PTL-I, PTL-II, ACA, BPL, BS-L, EEL, HHL, MALL-II, PHA-E+L, STL, SJA, LEL, PWM, MAL-I, GSL-I, and the combination of lectins DSA, ECA, LCA, WFA and lectins Jaclin, RCA120, AAL, LTL.

3. Use of a lectin combination in the preparation of a pan-vascular disease diagnostic chip, characterized in that: The lectin combination is: A combination of lectins PSA, UEA-I, and WGA, or a combination of lectins PSA, UEA-I, and WGA with one or more of lectins PTL-I, PTL-II, RCA120, AAL, and LTL, and a combination of lectins DSA, ECA, WFA, and LCA, or a combination of lectins DSA, ECA, WFA, and LCA with one or more of lectins ACA, ConA, DBA, EEL, GSL-I, GSL-II, PNA, SJA, PWM, NPA, MPL, HHL, and MAL-II.

4. The use of the lectin combination according to claim 3 in preparing a diagnostic chip for pan-vascular diseases, characterized in that: The lectin combination is: The combinations of lectins PSA, UEA-I, WGA with lectins PTL-I, PTL-II, RCA120, AAL, LTL, and the combinations of lectins DSA, ECA, WFA, LCA with lectins ACA, ConA, DBA, EEL, GSL-I, GSL-II, PNA, SJA, PWM, NPA, MPL, HHL, MAL-II.

5. Use of a lectin combination in preparing a chip for distinguishing coronary heart disease and panvascular disease, characterized in that: The lectin combination is: A combination of lectins PSA, UEA-I, and WGA, or a combination of lectins PSA, UEA-I, and WGA with one or more of lectins RCA120, AAL, LTL, Jaclin, and LCA, and a combination of lectins ECA and WFA, or a combination of lectins ECA and WFA with one or more of lectins ACA, BPL, BS-I, VVA, DBA, EEL, GSL-I, GSL-II, HHL, STL, MAL-I, MAL-II, MPL, NPA, PHA-E+L, PNA, PWM, SJA, ConA, and LEL.

6. Use of the lectin combination according to claim 5 in preparing a chip for distinguishing coronary heart disease and panvascular disease, characterized in that: The lectin combination is: The combination of lectins PSA, UEA-I, WGA with lectins RCA120, AAL, LTL, Jaclin, LCA, and the combination of lectins ECA, WFA with lectins ACA, BPL, BS-I, VVA, DBA, EEL, GSL-I, GSL-II, HHL, STL, MAL-I, MAL-II, MPL, NPA, PHA-E+L, PNA, PWM, SJA, ConA, LEL.

Images